JOHNSON & JOHNSON

NYSE: JNJ (Johnson & Johnson)

Last update: 1 hour ago

150.38

-2.51 (-1.64%)

  • 1D -1.64%
  • 5D 1.51%
  • 1M 4.91%
  • 6M -5.16%
  • YTD 4.42%
  • 1Y -5.64%
  • 5Y 0.59%
Previous Close 152.89
Open 152.66
Volume 7,716,950
Avg. Volume (3M) 8,367,157
Market Cap 362,057,924,608
Price / Earnings (TTM) 25.97
Price / Earnings (Forward) 13.64
Price / Sales 3.97
Price / Book 4.99
52 Weeks Range
140.68 (-6%) — 168.85 (12%)
Earnings Date 15 Apr 2025
TTM Dividend Yield 3.27%
Profit Margin 16.74%
Operating Margin (TTM) 24.52%
Diluted EPS (TTM) 5.80
Quarterly Revenue Growth (YOY) 5.20%
Quarterly Earnings Growth (YOY) -89.70%
Total Debt/Equity (MRQ) 50.96%
Current Ratio (MRQ) 1.03
Operating Cash Flow (TTM) 25.15 B
Levered Free Cash Flow (TTM) 19.92 B
Return on Assets (TTM) 8.40%
Return on Equity (TTM) 20.89%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Mixed Mixed
Drug Manufacturers - General (Global) Mixed Mixed
Stock Johnson & Johnson Bearish Bearish

AIStockmoo Score

1.0
Analyst Consensus 1.0
Insider Activity NA
Price Volatility 1.0
Technical Moving Averages 0.0
Technical Oscillators 2.0
Average 1.00

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
JNJ 362 B 3.27% 25.97 4.99
ABBV 310 B 3.54% 61.03 49.89
PFE 152 B 6.28% 35.67 1.65
BMY 121 B 4.02% - 7.06
GSK 70 B 4.54% 23.00 3.73
LLY 706 B 0.66% 84.63 50.52

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Value
% Held by Insiders 0.06%
% Held by Institutions 73.25%
52 Weeks Range
140.68 (-6%) — 168.85 (12%)
Price Target Range
152.00 (1%) — 190.00 (26%)
High 190.00 (Wolfe Research, 26.35%) Buy
Median 165.00 (9.72%)
Low 152.00 (Wells Fargo, 1.08%) Hold
Average 167.00 (11.05%)
Total 5 Buy, 6 Hold
Avg. Price @ Call 148.84
Firm Date Target Price Call Price @ Call
Barclays 28 Jan 2025 166.00 (10.39%) Hold 152.21
B of A Securities 23 Jan 2025 159.00 (5.73%) Hold 146.64
17 Jan 2025 160.00 (6.40%) Hold 147.03
Leerink Partners 23 Jan 2025 169.00 (12.38%) Buy 146.64
Morgan Stanley 23 Jan 2025 163.00 (8.39%) Hold 146.64
RBC Capital 23 Jan 2025 181.00 (20.36%) Buy 146.64
Raymond James 23 Jan 2025 165.00 (9.72%) Buy 146.64
Stifel 23 Jan 2025 155.00 (3.07%) Hold 146.64
Wells Fargo 23 Jan 2025 152.00 (1.08%) Hold 146.64
Citigroup 11 Dec 2024 175.00 (16.37%) Buy 146.64
Wolfe Research 15 Nov 2024 190.00 (26.35%) Buy 154.00
Guggenheim 06 Nov 2024 162.00 (7.73%) Hold 157.88
Show more

No data within this time range.

  • 3M
Date Type Details
23 Jan 2025 Announcement Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology
22 Jan 2025 Announcement Johnson & Johnson Reports Q4 and Full-Year 2024 Results
21 Jan 2025 Announcement SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
21 Jan 2025 CNBC FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
15 Jan 2025 Announcement New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer
13 Jan 2025 Announcement Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
13 Jan 2025 Announcement Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
09 Jan 2025 Announcement Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis
08 Jan 2025 Announcement Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
07 Jan 2025 Announcement RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib
07 Jan 2025 CNBC J&J says its lung cancer drug combination keeps people alive longer
02 Jan 2025 Announcement Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
12 Dec 2024 Announcement Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
11 Dec 2024 CNBC SpaceX valuation surges to $350 billion as company buys back stock
10 Dec 2024 Announcement Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
09 Dec 2024 Announcement Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options
09 Dec 2024 Announcement CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 study
08 Dec 2024 Announcement DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma
08 Dec 2024 Announcement TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
08 Dec 2024 Announcement DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myeloma
02 Dec 2024 Announcement Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)
22 Nov 2024 Announcement Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
19 Nov 2024 Announcement Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting
18 Nov 2024 Announcement Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
14 Nov 2024 Announcement Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
11 Nov 2024 Announcement Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease
08 Nov 2024 Announcement Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
07 Nov 2024 Announcement Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
07 Nov 2024 CNBC FDA proposes ending use of decongestant found in many cold, allergy medicines
28 Oct 2024 Announcement TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
Show more
TTM Dividend Yield 3.27%
5Y Average Dividend Yield 2.78%
Payout Ratio 80.33%
Expected Next Dividend Payment Jun 2025
Ex Date Announcement Date Payment Date Details
18 Feb 2025 02 Jan 2025 04 Mar 2025 1.24 Cash
26 Nov 2024 15 Oct 2024 10 Dec 2024 1.24 Cash
27 Aug 2024 17 Jul 2024 10 Sep 2024 1.24 Cash
20 May 2024 16 Apr 2024 04 Jun 2024 1.24 Cash
16 Feb 2024 02 Jan 2024 05 Mar 2024 1.19 Cash
20 Nov 2023 19 Oct 2023 05 Dec 2023 1.19 Cash
25 Aug 2023 20 Jul 2023 07 Sep 2023 1.19 Cash
22 May 2023 18 Apr 2023 06 Jun 2023 1.19 Cash
17 Feb 2023 03 Jan 2023 07 Mar 2023 1.13 Cash
21 Nov 2022 19 Oct 2022 06 Dec 2022 1.13 Cash
22 Aug 2022 18 Jul 2022 06 Sep 2022 1.13 Cash
23 May 2022 19 Apr 2022 07 Jun 2022 1.13 Cash
18 Feb 2022 04 Jan 2022 08 Mar 2022 1.06 Cash
22 Nov 2021 21 Oct 2021 07 Dec 2021 1.06 Cash
23 Aug 2021 19 Jul 2021 07 Sep 2021 1.06 Cash
24 May 2021 06 May 2021 08 Jun 2021 1.06 Cash
22 Feb 2021 04 Jan 2021 09 Mar 2021 1.01 Cash
23 Nov 2020 22 Oct 2020 08 Dec 2020 1.01 Cash
24 Aug 2020 20 Jul 2020 08 Sep 2020 1.01 Cash
22 May 2020 14 Apr 2020 09 Jun 2020 1.01 Cash
24 Feb 2020 02 Jan 2020 10 Mar 2020 0.95 Cash
25 Nov 2019 18 Oct 2019 10 Dec 2019 0.95 Cash
26 Aug 2019 16 Jul 2019 10 Sep 2019 0.95 Cash
24 May 2019 26 Apr 2019 11 Jun 2019 0.95 Cash
25 Feb 2019 02 Jan 2019 12 Mar 2019 0.9 Cash
26 Nov 2018 18 Oct 2018 11 Dec 2018 0.9 Cash
27 Aug 2018 17 Jul 2018 11 Sep 2018 0.9 Cash
25 May 2018 26 Apr 2018 12 Jun 2018 0.9 Cash
26 Feb 2018 02 Jan 2018 13 Mar 2018 0.84 Cash
27 Nov 2017 19 Oct 2017 12 Dec 2017 0.84 Cash
25 Aug 2017 17 Jul 2017 12 Sep 2017 0.84 Cash
25 May 2017 27 Apr 2017 13 Jun 2017 0.84 Cash
24 Feb 2017 03 Jan 2017 14 Mar 2017 0.8 Cash
18 Nov 2016 20 Oct 2016 06 Dec 2016 0.8 Cash
19 Aug 2016 18 Jul 2016 06 Sep 2016 0.8 Cash
20 May 2016 28 Apr 2016 07 Jun 2016 0.8 Cash
19 Feb 2016 04 Jan 2016 08 Mar 2016 0.75 Cash
20 Nov 2015 22 Oct 2015 08 Dec 2015 0.75 Cash
21 Aug 2015 20 Jul 2015 08 Sep 2015 0.75 Cash
21 May 2015 23 Apr 2015 09 Jun 2015 0.75 Cash
20 Feb 2015 05 Jan 2015 10 Mar 2015 0.7 Cash
21 Nov 2014 16 Oct 2014 09 Dec 2014 0.7 Cash
22 Aug 2014 21 Jul 2014 09 Sep 2014 0.7 Cash
22 May 2014 24 Apr 2014 10 Jun 2014 0.7 Cash
21 Feb 2014 02 Jan 2014 11 Mar 2014 0.66 Cash
22 Nov 2013 17 Oct 2013 10 Dec 2013 0.66 Cash
23 Aug 2013 15 Jul 2013 10 Sep 2013 0.66 Cash
23 May 2013 25 Apr 2013 11 Jun 2013 0.66 Cash
22 Feb 2013 02 Jan 2013 12 Mar 2013 0.61 Cash
23 Nov 2012 17 Oct 2012 11 Dec 2012 0.61 Cash
24 Aug 2012 16 Jul 2012 11 Sep 2012 0.61 Cash
24 May 2012 26 Apr 2012 12 Jun 2012 0.61 Cash
24 Feb 2012 03 Jan 2012 13 Mar 2012 0.57 Cash
25 Nov 2011 21 Oct 2011 13 Dec 2011 0.57 Cash
26 Aug 2011 18 Jul 2011 13 Sep 2011 0.57 Cash
26 May 2011 28 Apr 2011 14 Jun 2011 0.57 Cash
25 Feb 2011 03 Jan 2011 15 Mar 2011 0.54 Cash
26 Nov 2010 21 Oct 2010 14 Dec 2010 0.54 Cash
27 Aug 2010 19 Jul 2010 14 Sep 2010 0.54 Cash
27 May 2010 22 Apr 2010 15 Jun 2010 0.54 Cash
19 Feb 2010 04 Jan 2010 09 Mar 2010 0.49 Cash
20 Nov 2009 22 Oct 2009 08 Dec 2009 0.49 Cash
21 Aug 2009 20 Jul 2009 08 Sep 2009 0.49 Cash
21 May 2009 23 Apr 2009 09 Jun 2009 0.49 Cash
20 Feb 2009 05 Jan 2009 10 Mar 2009 0.46 Cash
21 Nov 2008 16 Oct 2008 09 Dec 2008 0.46 Cash
22 Aug 2008 21 Jul 2008 09 Sep 2008 0.46 Cash
22 May 2008 24 Apr 2008 10 Jun 2008 0.46 Cash
22 Feb 2008 02 Jan 2008 11 Mar 2008 0.415 Cash
23 Nov 2007 18 Oct 2007 11 Dec 2007 0.415 Cash
24 Aug 2007 16 Jul 2007 11 Sep 2007 0.415 Cash
24 May 2007 26 Apr 2007 12 Jun 2007 0.415 Cash
23 Feb 2007 03 Jan 2007 13 Mar 2007 0.375 Cash
24 Nov 2006 19 Oct 2006 12 Dec 2006 0.375 Cash
25 Aug 2006 18 Jul 2006 12 Sep 2006 0.375 Cash
25 May 2006 27 Apr 2006 13 Jun 2006 0.375 Cash
18 Nov 2005 20 Oct 2005 13 Dec 2005 0.33 Cash
19 Aug 2005 18 Jul 2005 13 Sep 2005 0.33 Cash
13 May 2005 28 Apr 2005 07 Jun 2005 0.33 Cash
11 Feb 2005 04 Jan 2005 08 Mar 2005 0.285 Cash
12 Nov 2004 22 Oct 2004 07 Dec 2004 0.285 Cash
13 Aug 2004 20 Jul 2004 07 Sep 2004 0.285 Cash
14 May 2004 22 Apr 2004 08 Jun 2004 0.285 Cash
12 Feb 2004 05 Jan 2004 09 Mar 2004 0.24 Cash
14 Nov 2003 16 Oct 2003 09 Dec 2003 0.24 Cash
15 Aug 2003 22 Jul 2003 09 Sep 2003 0.24 Cash
16 May 2003 24 Apr 2003 10 Jun 2003 0.24 Cash
13 Feb 2003 06 Jan 2003 11 Mar 2003 0.205 Cash
15 Nov 2002 15 Oct 2002 10 Dec 2002 0.205 Cash
16 Aug 2002 15 Jul 2002 10 Sep 2002 0.205 Cash
17 May 2002 25 Apr 2002 11 Jun 2002 0.205 Cash
14 Feb 2002 02 Jan 2002 12 Mar 2002 0.18 Cash
16 Nov 2001 18 Oct 2001 11 Dec 2001 0.18 Cash
17 Aug 2001 16 Jul 2001 11 Sep 2001 0.18 Cash
18 May 2001 26 Apr 2001 12 Jun 2001 0.36 Cash
15 Feb 2001 02 Jan 2001 13 Mar 2001 0.32 Cash
17 Nov 2000 16 Oct 2000 12 Dec 2000 0.32 Cash
18 Aug 2000 17 Jul 2000 12 Sep 2000 0.32 Cash
19 May 2000 19 Apr 2000 13 Jun 2000 0.32 Cash
11 Feb 2000 03 Jan 2000 07 Mar 2000 0.28 Cash
12 Nov 1999 18 Oct 1999 07 Dec 1999 0.28 Cash
13 Aug 1999 19 Jul 1999 07 Sep 1999 0.28 Cash
14 May 1999 22 Apr 1999 08 Jun 1999 0.28 Cash
11 Feb 1999 04 Jan 1999 09 Mar 1999 0.25 Cash
13 Nov 1998 19 Oct 1998 08 Dec 1998 0.25 Cash
14 Aug 1998 20 Jul 1998 08 Sep 1998 0.25 Cash
15 May 1998 23 Apr 1998 09 Jun 1998 0.25 Cash
12 Feb 1998 02 Jan 1998 10 Mar 1998 0.22 Cash
14 Nov 1997 20 Oct 1997 09 Dec 1997 0.22 Cash
15 Aug 1997 21 Jul 1997 09 Sep 1997 0.22 Cash
16 May 1997 24 Apr 1997 10 Jun 1997 0.22 Cash
13 Feb 1997 02 Jan 1997 11 Mar 1997 0.19 Cash
15 Nov 1996 21 Oct 1996 10 Dec 1996 0.19 Cash
16 Aug 1996 15 Jul 1996 10 Sep 1996 0.19 Cash
17 May 1996 25 Apr 1996 11 Jun 1996 0.38 Cash
15 Feb 1996 02 Jan 1996 12 Mar 1996 0.33 Cash
10 Nov 1995 16 Oct 1995 05 Dec 1995 0.33 Cash
11 Aug 1995 17 Jul 1995 05 Sep 1995 0.33 Cash
10 May 1995 27 Apr 1995 06 Jun 1995 0.33 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2025 1.24 1 0.82
2024 4.91 4 3.40
2023 4.70 4 3.00
2022 4.45 4 2.52
2021 4.19 4 2.45
2020 3.98 4 2.53
2019 3.75 4 2.57
2018 3.54 4 2.74
2017 3.32 4 2.38
2016 3.15 4 2.73
2015 2.95 4 2.87
2014 2.76 4 2.64
2013 2.59 4 2.83
2012 2.40 4 3.42
2011 2.25 4 3.43
2010 2.11 4 3.41
2009 1.93 4 3.00
2008 1.80 4 3.00
2007 1.62 4 2.43
2006 1.13 3 1.70
2005 1.28 4 2.12
2004 1.10 4 1.73
2003 0.925 4 1.79
2002 0.795 4 1.48
2001 1.04 4 1.76
2000 1.24 4 2.36
1999 1.09 4 2.34
1998 0.970 4 2.31
1997 0.850 4 2.58
1996 1.09 4 4.38
1995 0.990 3 4.63
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria